Document:

Exhibit 10.2

 Exhibit 10.2 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

ADDENDUM 1 
 No.
012174-1NOHL-01 
 TO THE PARTNERSHIP AGREEMENT No. 012174-1NOHL-OO 

This Project Addendum 1 (the “Project Addendum 1”) is made and entered into as of 2 April 2013 (the “Project Addendum 1
Effective Date”), by and between GenSight Biologics SA, a corporation organized under the laws of France, registered with the Lyon Trade and Company Registry under number B 751 164 757 (SIRET: 75116475700013), with its principal place of
business at 1bis Allée du Sauze, 69160 Tassin la Demi-Lune, France (“GenSight”), and Genethon, a non-profit organization organized under the laws of France, with its principal place of
business at 1bis, rue de l’Internationale, 91002 Evry Cedex, France (SIRET: 40218752000018) (“Genethon”), (each of GenSight and Genethon a “Party” individually and collectively the “Parties”).

 BACKGROUND 

WHEREAS, the Parties entered into a partnership agreement No. 012174-1NOHL-OO on February 1, 2013 (the “Partnership
Agreement”); 
 WHEREAS, the Parties agree to conclude Project Addenda in separate written contract to perform a given
R&D Project; each Project Addendum shall (i) set forth the specific conditions applicable to the corresponding R&D Project; and (ii) contain the corresponding R&D Project Program as well as a list of the Parties’
respective Pre-Existing Know-How necessary or helpful for carrying out the corresponding R&D Project; 
 WHEREAS, the Parties
agreed on a Research Program around the Leber’s Hereditary Optic Neuropathy (“LHON”) program and wish to execute this Project Addendum 1 to agree on the specific conditions of this Research Program; 

NOW THEREFORE, in consideration of the mutual covenants, conditions and undertakings herein contained, the Parties agree as follows:

  

	 	1.	OBJECT OF THIS PROJECT ADDENDUM 1 

 The Parties agree on the conditions of the LHON
Research Program described in Exhibit 2A here-attached. 
  

	 	2.	DURATION 

 This Project Addendum 1 enters into force on the Project Addendum 1 Effective
Date for the duration of the LHON Research Program. 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 1 

	 	3.	INTANGIBILITY OF UNMODIFIED CLAUSES 

 All the terms and conditions of the Partnership Agreement that have
not been modified by and that are not in contradiction to this Project Addendum 1 shall apply. Capitalized terms used in this Project Addendum 1 and not otherwise defined shall have the meaning ascribed to such terms in the Partnership Agreement. As
of the Project Addendum 1 Effective Date, any reference to the Project Addendum 1 shall be deemed a reference to the Partnership Agreement as amended by this Project Addendum 1. 

IN WITNESS WHEREOF, the Parties have caused their duly authorized representatives to execute this Agreement. 

 

					
	Gensight Biologics SA				Genethon
	/s/ Bernard Gilly				/s/ Frédéric Revah
	Title: CEO				Title: CEO

  
 2 

 EXHIBIT 2A 

LHON Project Addendum 
  

[**] 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 3 

 APPENDIX 1 of LHON Project Addendum 

[**] 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 4 

 APPENDIX 2 of LHON Project Addendum: FORECASTED LHON PRODUCTION REQUIREMENTS 

[**] 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 5 

 NOHL Project Addendum Appendix 3: CLINICAL DEVELOPMENT PLAN 

AGREED TIMELINES ON 18 APRIL 2013 
 [**] 

 

			
	Version dated 18 April 2013		

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 6Exhibit 10.3

 Exhibit 10.3 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

ADDENDUM 1.1 

No. 012174-1NOHL-01.1 

TO THE PARTNERSHIP AGREEMENT No. 012174-1NOHL-OO 

This Project Addendum 1.1 (the “Project Addendum 1.1”) is made and entered into as of 1 January 2014 (the “Project
Addendum 1.1 Effective Date”), by and between GenSight Biologics SA, a corporation organized under the laws of France, registered with the Lyon Trade and Company Registry under number B 751 164 757 (SIRET: 75116475700013), with its
principal place of business at 74 rue du Faubourg Saint Antoine 75012 Paris, France (“GenSight”), and Genethon, a non-profit organization organized under the laws of France, with its principal place of business at 1bis, rue de
l’Internationale, 91002 Evry Cedex, France (SIRET: 40218752000018) (“Genethon”), (each of GenSight and Genethon a “Party” individually and collectively the “Parties”). 

BACKGROUND 

WHEREAS, the Parties entered into a partnership agreement No. 012174-1 NOHL-00 on February 1, 2013 (the “Partnership
Agreement”), and agreed on the specific conditions of the Leber’s Hereditary Optic Neuropathy (“LHON”) program (the “LHON Research Program”) in a first addendum dated 2 April 2013 (the
“Project Addendum 1”) (the Partnership Agreement and its Project Addendum 1 are hereafter referred to as the “LHON Partnership Agreement”); 

WHEREAS, the Parties agree to extend Genethon’s activities in the framework of the LHON Research Program, in particular regarding
further process development, GMP manufacturing for future commercial batches covering EU and USA territories, clinical and regulatory support activities and the provision of a project development plan. 

NOW THEREFORE, in consideration of the mutual covenants, conditions and undertakings herein contained, the Parties agree as follows:

  

	 	1.	OBJECT OF THIS PROJECT ADDENDUM 1.1 

  

	 	1.1	The Parties agree to modify the conditions of the LHON Research Program relating to clinical and regulatory support as described in Exhibit 2A of the Project Addendum 1 in particular in section 4 with the conditions set
forth in Exhibit 2B here-attached. The Parties agree to re-negotiate whether clinical support by Genethon will still be desired by GenSight and agreed by Genethon following the end of the period contracted for clinical support by
Genethon, which is October 31, 2014, and if so the amount to be paid by GenSight regarding such continued activities. 

  

	 	1.2	As mentioned in section 5 of Exhibit 2A of the Project Addendum 1, the Parties agree to further develop the manufacturing process to support the later stages of clinical development and eventual commercial sales. In
this context, Genethon has provided to GenSight a project development plan as attached in Exhibit 2C section B of this Project Addendum 1.1 with the amount to be paid by GenSight regarding such activities indicated in Exhibit 2C section A of
this Project Addendum 1.1. Such development plan and activities are also related to a quality agreement that is under discussion between both parties for defining, establishing and documenting the responsibilities of each party involved in the
contract manufacturing of LHON Research Program subject to current Good manufacturing practice (CGMP). 

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 1 

	 	2.	STRATEGIC COMMITTEE 

 In accordance with section 3.1 of the Partnership Agreement, the
Parties agree to modify the GenSight’s authorized representatives to the Strategic Committee. Said authorized representative will be (i) the “chief operating officer” or the “directeur general” (any of them
referred to the “D” as mentioned in the Partnership Agreement) and (ii) one senior scientist (“SC Member”). 
  

	 	3.	DURATION 

 This Project Addendum 1.1 enters into force on the Project Addendum 1.1
Effective Date for the duration of the LHON Research Program. 
  

	 	4.	INTANGIBILITY OF UNMODIFIED CLAUSES 

 All the terms and conditions of the LHON
Partnership Agreement and its Project Addendum 1 that have not been modified by, and that are not in contradiction to, this Project Addendum 1.1 shall apply. Capitalized terms used in this Project Addendum 1.1 and not otherwise defined shall have
the meaning ascribed to such terms in the LHON Partnership Agreement. As of the Project Addendum 1.1 Effective Date, any reference to the Project Addendum 1.1 shall be deemed a reference to the LHON Partnership Agreement as amended by this Project
Addendum 1.1. 
 IN WITNESS WHEREOF, the Parties have caused their duly authorized representatives to execute this Project
Addendum 1.1. 
  

					
			GenSight Biologics SA		Genethon
			/s/ Bernard Gilly		/s/ Frédéric Revah
			Title: CEO		Title: CEO

  
 2 

 EXHIBIT 2B 

LHON Project Addendum 
  

[**] 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 3 

 EXHIBIT 2C 

LHON Project Addendum Amendment 

 
 [**] 

 

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 4Exhibit 10.4

 Exhibit 10.4 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

RESEARCH COLLABORATION AGREEMENT 

This Research Collaboration Agreement (the “Agreement”) having an Effective Date of March 1st, 2014, is made between the
Friedrich Miescher Institute for Biomedical Research (“FMI”) located at Maulbeerstrasse 66, 4058 Basel, Switzerland, (Principal Investigator Dr. Botond Roska), and GenSight Biologics, located at 89 Rue du Fbg Saint Antoine, 75011
Paris, France (“GenSight”), (Principal Investigator Dr. Didier Pruneau), under the following terms and conditions. 
  

	 	1.	Research Project. FMI and GenSight (the “Parties”) desire to undertake collaborative research activities for the purpose of to be completed by FMI Towards this goal FMI and GenSight will exchange
material and know-how. The project will be conducted at the Roska Lab of the FMI by Dr. Tamas Szikra. GenSight shall contribute to said research work by subvention to FMI following GenSight’s receipt of an invoice. GenSight contribution
will be done according to the following scheme: 

  

	 	•	 	Issuance of credit payment to FMI for subvention of research work in March 2014: 111,240 EUR. 

  

	 	•	 	Issuance of credit payment to FMI for subvention of research work in March 2015: 111,240 EUR. 

  

	 	•	 	Issuance of credit payment to FMI for subvention of research work in March 2016: 111,240 EUR. 

  

	 	2.	Transfer of Materials and Information Among Parties. Biological and other research materials, as hereinafter defined, may be transferred between FMI and GenSight in connection with the Research Project.
The following terms shall govern any transfer of materials pursuant to the Research Project. 

  

	 	a.	In General. It is expected that materials developed outside the course of the Research Project will be exchanged between GenSight and FMI. In addition, other materials developed during the course of the
Research Project may be transferred between the Parties, as agreed upon by the aforementioned principal investigators, as part of the Research Project under the terms of this Agreement. The original research material provided by FMI and any progeny
and unmodified derivatives and any additional materials transferred between the Parties under this paragraph 2a shall be owned solely by FMI (“FMI Materials”). The original research material provided by GenSight and any progeny and
unmodified derivatives and any additional materials transferred between the Parties under this Paragraph 2a shall be owned solely by the Institution (“GenSight Materials”). Materials developed jointly by researchers at FMI and GenSight in
the course of the Research Project will be owned jointly by GenSight and FMI (“Jointly Developed Materials”). All such materials are sometimes hereinafter referred to as Research Materials, singly or collectively. 

 

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 1 

	 	b.	Research Materials. All Research Materials transferred in connection with the Research Project are experimental in nature and shall be used with prudence and appropriate caution, since not all of their
characteristics are known. ALL RESEARCH MATERIALS ARE PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. A Party providing its Research Materials (the
“Provider”) makes no representation or warranty to the receiving party (the “Recipient”) that the use of such Research Materials will not infringe any patent or other proprietary right. However, FMI, to the best of its knowledge
and experience, represents and warrants to GenSight that there are no rights or obligations owed by FMI to any third party that may restrict or impair GenSight’s use of the FMI Materials as contemplated by this Agreement 

Novartis Pharma AG has certain rights in Research Results developed by FMI under the Research and Proprietary Rights Agreement (RPRA),
effective as of January 1, 2012. 
  

	 	c.	Legal Title; Use. Legal title to any Research Materials transferred hereunder shall be unaffected by this Agreement or the transfer made hereunder. GenSight will use FMI Materials only in work done in the
course of the Research Project, and only in the laboratory of GenSight’s Principal Investigator in research by laboratory personnel under that Principal Investigator’s immediate and direct control. In addition, during the term of the
Research Project, any Jointly Developed Materials will not be used by the Parties other than in the Research Project. 

  

	 	d.	Limitations. Research Materials transferred under this Agreement are provided only for use in animals or in vitro. Research Materials transferred under this Agreement will not be used
in humans, including for purposes of diagnostic testing. Any use of Research Materials by the transferee, other than in accordance with this paragraph 2, is a material breach of this Agreement for purposes for the termination
provisions of paragraph 8, below. 

  

	 	e.	Recipient Rights in Transferred Materials. The transfer of Materials between FMI and GenSight gives the Recipient no rights in such material other than those specifically set forth in this
Agreement. 

  

	 	3.	 Confidentiality. Subject to paragraph 5, below, during the term of this Agreement and for a period of five years thereafter, Recipient
shall cause all information that is disclosed to it by Provider in connection with the Research Project and that is identified in writing as confidential by Provider (“Confidential Information”), to be treated according to the same
internal security procedures and with the same degree of care regarding its secrecy and confidentiality as Recipient treats similar information of its own. Confidential Information does not include information that (i) is or later becomes
available to the public through no fault of Recipient or its representative; (ii) is obtained from a third party who had the legal right to disclose the information; (iii) as of the date of disclosure, is already in the possession of
Recipient (and such prior possession can be properly demonstrated by Recipient); (iv) is required to be disclosed 

  
 2 

	 	
by law, government regulation, rule, act or court order (but only to the extent so required); or (v) is independently developed by Recipient (and such independent development can be properly
demonstrated by Recipient). 

  

	 	4.	Results of Research Project. 

  

	 	a.	In General. Each Party will submit the research results obtained from its work in connection with the Research Project to the other Party. Information shared in accordance with this paragraph
shall be treated as Confidential Information by the Recipient (even if not identified as Confidential Information by Provider) and shall be handled by Recipient in accordance with the procedures set forth in paragraph 3, above. Each Party and its
Affiliates shall have an unrestricted right to use for its own internal non-commercial research purposes all research results, including without limitation any Sole Invention of any Party and any Joint Invention (as such terms are defined below),
obtained from the Research Project. 

 b. Inventions. For the purpose of determining ownership under this
paragraph, inventorship of Inventions will be determined in accordance with principles of U.S. patent law. An “Invention” is any invention or discovery, whether patentable or non-patentable, or
copyrightable or non-copyrightable, that is conceived or reduced to practice in the course of and during the performance of the Research Project by at least Dr. Tamas Szikra. In the case of a non-patentable Invention, inventorship will be
determined under such principles by treating such Invention as if it were patentable. Subject to paragraph 2a, if an Invention is made by one or more inventors all of whom are required to assign rights in the Invention to a single Party (a
“Sole Invention”), the Sole Invention shall be the property of that Party. If an Invention is made by more than one inventor, and at least one inventor is required to assign rights in the Invention to FMI and at least one inventor is
required to assign rights in the Invention to GenSight, the Invention shall be jointly owned by the Parties who are assigned rights in the Invention (a “Joint Invention”). GenSight and FMI may pursue joint patent protection of Joint
Inventions. If either Party chooses not to file a patent application, it may relinquish its rights to the other Party. Thereafter, the other Party may file the patent application in its own name, and at its own expense. In any event, the
relinquishing Party and its Affiliates shall retain all research use licenses granted herein. “Affiliates” shall mean any entity or subsidiary which controls a Party. For purposes of this definition, “control” or
“controlled” shall mean ownership directly or through one or more Affiliates, of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent
(50%) or more of the equity interest in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby a Party controls or has the right to control the Board of Directors or
equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or policies of a corporation or other entity. The Parties acknowledge that in the case of certain entities organized under the laws
of certain countries outside of the US, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage shall be substituted in the preceding sentence,
provided that such foreign investor has the power to direct the management and policies of such entity. 

  
 3 

	 	c.	Options and Rights of Novartis. Under conditions detailed in and in line with the RPRA, Novartis Pharma AG and Affiliates, shall have an option to obtain at the sole discretion of Novartis Pharma AG, a
worldwide, non exclusive license with the right to grant sub licenses to Affiliates of Novartis Pharma AG to make, have made use and sell any FMI Sole Inventions or the FMI share of any Joint Inventions. 

 

	 	d.	Options and Rights of Gensight Biologics. 

 Gensight Biologics shall have an
option to obtain at its sole discretion a worldwide, non exclusive license with the right to grant sub licenses to its Affiliates to make, have made use and sell any FMI Sole Inventions. 

In case Novartis Pharma AG does not exercise its option (according to paragraph c) to obtain a worldwide, non exclusive license on any FMI Sole
Inventions, then Gensight Biologics shall have an option to obtain at its sole discretion a worldwide, exclusive license with the right to grant sub licenses to its Affiliates to make, have made use and sell any FMI Sole Inventions. 

 

	 	e.	Reports 

 Annual report will be provided to GenSight of study progress,
publications and patents submission on the anniversary date. 
  

	5.	Publication. The Parties will consult with one another about how best to manage external publications of collaborative work and will cooperate in coordinating external presentations of any research results
obtained under this Agreement. Authorship of results of the Research Project will be determined in accordance with academic standards and custom. Proper acknowledgement will be made for the contributions of each Party to the research results being
published. If a proposed publication is not a joint publication, the Party wishing to make the publication shall provide a copy of the manuscript or abstract to the other Party at least [**] days prior to submission of the manuscript or abstract for
publication in order to allow the other Party an opportunity to protect proprietary information or intellectual property that might be disclosed by the manuscript or abstract. In addition, a Party will not publish Confidential Information received
from the other Party without such other Party’s prior written consent. 

  

	6.	Responsibilities of the Parties. Except to the extent prohibited by law, each Party is responsible and liable to the other Party only for its own acts and omissions, and the acts and omissions of its
trustees, directors, officers, employees, and agents, relating to the Research Project or to any Research Materials that have been transferred to it in connection with the Research Project. The Parties agree to indemnify and hold each other and its
respective trustees, directors, officers, employees, and agents harmless from any claim, liability, cost, expense, damage, deficiency, loss or obligation, of any kind or nature (including without limitation, reasonable attorneys’ fees)
(collectively, “Claims”) resulting from the other Parties acts or omissions, or those of its trustees, directors, officers, employees, or agents, under, arising out of or otherwise related to this Agreement, the Research Project or the
Research Materials transferred in connection with the Research Project, except to the extent such Claim arises out of the gross negligence or intentional wrongdoing of the Party seeking indemnification or that of its trustees, directors, officers,
employees or agents. 

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 4 

	7.	Compliance with Laws and Regulations. All research done in connection with the Research Project, including all use of Research Materials transferred hereunder, will be done in compliance with all laws,
governmental regulations and guidelines. 

  

	8.	Term of Agreement: Duration of Research Project. This Agreement shall go into effect on the Effective Date. This Agreement shall continue in effect until February 28th, 2017. In the event of a
material breach of this Agreement by a Party, the non-breaching Party may terminate the Research Project and this Agreement following [**] days’ written notice to the other Party and failure to cure the
breach by the breaching Party during such [**]-day period. If the Research Project and this Agreement are terminated, GenSight Materials and Confidential Information received pursuant to this Agreement by FMI shall, at the request of GenSight, be
returned to GenSight or properly destroyed. The terms of paragraphs 2, 4, 5, 6, 9, 10 and 15 and of paragraph 3 as specified therein, and of this sentence and the preceding sentence, shall survive any termination of this Agreement.

  

	9.	Assignment. This Agreement is not assignable by a Party, whether by operation of law or otherwise, without the prior written consent of the other Party, except to an Affiliate of such Party. Any attempt to
assign in violation of this Section 9 shall be void and without effect. 

  

	10.	Governing Law. This Agreement shall be governed by and construed in accordance with the law of Basel-Stadt, Switzerland. 

 

	11.	Independent Parties. GenSight and FMI shall, at all times, act as independent Parties and nothing contained in this Agreement shall be construed or implied to create an agency, partnership or other joint
enterprise between the Parties. 

  

	12.	Severability. If any one or more of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions of this
Agreement shall not in any way be affected or impaired thereby. 

  

	13.	Notices. Any notice or communication provided for in this Agreement to be made by either of the Parties to the other shall be in writing, in English, and shall be made by prepaid registered or certified
mail with return receipt or by express overnight courier addressed to the other at its address set forth below. Notices shall be sent: 

  

			
	If to FMI, to:		Dr. Nicolas Favre
		
			Head Patents & Licensing
		
			Friedrich Miescher Institute for Biomedical Research Maulbeerstrasse 66
		
			 CH-4058 Basel
  

Switzerland

		
			Fax: +41 61 697 53 23

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 5 

			
		
	If to GenSight, to:		GenSight Biologics
		
			89 Rue du Fbg Saint Antoine 75011 Paris, France
		
			Attention: Didier Pruneau

  

	14.	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument. 

 

	15.	Entire Agreement. This Agreement between the Parties sets forth all of the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with
respect to the Research Project, and supersedes all previous written and oral communications. No amendment, alteration or modification of this Agreement or any exhibits attached hereto shall be valid unless executed in writing by authorized
signatories of both Parties. 

  

			
	GenSight Biologics		Friedrich Miescher Institute for Research
	/s/ Bernard Gilly		/s/ Prof. Dr. Susan Grasser
	Title: CEO		Title: Director
		
			/s/ Dr. Nicolas Favre
			Title: Head Patents & Licensing
		
			 Read and Acknowledges:

			/s/ Dr. Botond Roska
			Title: Group Leader

  
 6 

 Summary of Research Project: 

[**] 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}]]